194 patents
Page 4 of 10
Utility
Universal donor cells
6 Sep 22
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 23 Jul 21
Utility
Allogeneic Cell Therapy of B Cell Malignancies Using Genetically Engineered T Cells Targeting CD19
11 Aug 22
A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.
Mark Benton, Tony Ho, Demetrios Kalaitzidis, Ewelina Morawa, Jonathan Alexander Terrett
Filed: 30 Apr 20
Utility
ba5mtujahbeums4v1cg r0gs0jhqv
9 Aug 22
The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with AGXT, both ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 21 Feb 18
Utility
4fu o5twqnvnhfrsmgtrhj3wsxvvye765xtg5
21 Jul 22
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as CD33+ malignancies.
Jonathan Alexander Terrett, Jason Sagert, Demetrios Kalaitzidis
Filed: 7 Nov 19
Utility
9g8ocgcp5ahr4b018m78bslnvoypxtiy1l6f3unz8mf8yas2gnf0sp
19 Jul 22
A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.
Mark Benton, Tony Ho, Demetrios Kalaitzidis, Ewelina Morawa, Jonathan Alexander Terrett
Filed: 22 Apr 21
Utility
vwtli3 oso2qwykd2zl8swzxumdvggpotj
14 Jul 22
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Valentin Sluch
Filed: 31 Dec 21
Utility
ech7cq bt8of47lkpl0xtg3f
30 Jun 22
Combined therapy for treating multiple myeloma (MM), comprising (a) a population of genetically engineered T cells, which may express a chimeric antigen receptor (CAR) that binds B-cell maturation antigen (BCMA), and (b) an anti-CD38 antibody such as daratumumab or lenalidomide or a derivative thereof.
Jonathan Alexander TERRETT, Ewelina MORAWA, Jason SAGERT, Annie Yang WEAVER
Filed: 22 Dec 21
Utility
w1yfnn grh9fseqvem8vjkuyb5zj2go7uam0j37xnpaoa0
30 Jun 22
The disclosure features methods and compositions for differentiating stem cells into hematopoietic stem and progenitor cells (HSPC) and/or Natural Killer (NK) cells.
Viktoriia KYRYCHENKO, Wai Lun LEUNG, Alireza REZANIA, Patrick Claudio OVANDO ROCHE
Filed: 30 Nov 21
Utility
ak4cfm1hk7v826wl 07gxjlz8cjhbub5m8vq
30 Jun 22
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Valentin Sluch
Filed: 31 Dec 21
Utility
qmalexwta2oduav9vmggn0j3mw2vr ryipcpphxoy61xu5nwk
23 Jun 22
A method for producing T cells expressing a chimeric antigen receptor (CAR-T cells), comprising: (i) culturing CAR-T cells in a medium comprising lenalidomide or a derivative thereof to produce CAR-T cells, and optionally (ii) administering the CAR-T cells to a subject in need of the treatment.
Henia DAR, Jason SAGERT, Jonathan Alexander TERRETT, Hui YU
Filed: 22 Dec 21
Utility
6mrewmavke1tnnkyd2533l4uum ni22ijw7wjbtwtnk
2 Jun 22
The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15Rα, and/or HLA-E.
Viktoriia KYRYCHENKO, Wai Lun LEUNG, Alireza REZANIA, Valentin SLUCH, Danielle SWAIN, Patrick Claudio OVANDO ROCHE
Filed: 30 Nov 21
Utility
9revyeghgr6hxzsh79k8p0zvu7p5ydfbqlqcis257oftnba6zry9lu
2 Jun 22
The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15Rα, and/or HLA-E.
Viktoriia KYRYCHENKO, Wai Lun LEUNG, Alireza REZANIA, Valentin SLUCH, Danielle SWAIN, Patrick Claudio OVANDO ROCHE
Filed: 30 Nov 21
Utility
vpaz77qo60uqekksxrn4n631c3
17 May 22
The present disclosure provides donor polynucleotides, genome editing systems, methods, pharmaceutical compositions, and kits which correct or induce a mutation that causes Glycogen Storage Disease 1a in a genomic DNA (gDNA) molecule in a cell.
Troy Dean Carlo, Roman Lvovitch Bogorad
Filed: 18 Feb 21
Utility
36ww64jsxcf11y3csv6uc9s6r1ui5wdt1dkt6yzbdm7busufrpm
12 May 22
Described herein are novel systems for targeting, editing or manipulating DNA in a cell, using novel M-SmallCas9 nucleases and variants thereof.
Moritz Schmidt, Philipp Knyphausen, Christina Galonska, Wayne Coco, Andre Cohnen
Filed: 12 Mar 20
Utility
qxcyuuz90yh28 4n03bjn7k12rpsa4d7lyh53huixaixjpkcnb6z9sd1q
21 Apr 22
A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted β2M gene, or both, for use in treating a B cell malignancy.
Mark BENTON, Tony HO, Demetrios KALAITZIDIS, Ewelina MORAWA, Jonathan Alexander TERRETT
Filed: 19 Oct 21
Utility
t89uo3tx47j0 krokstvpgwzw09j4rb9u9hgwkbibg91l0mhxqv91scfsrag
24 Mar 22
A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene.
Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
Filed: 4 Oct 21
Utility
ujs93cifj4ofcfkd3zb9pv98eqzev2c8 gmxf5twwubzkemujwiyc153gw5
24 Mar 22
A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene.
Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
Filed: 4 Oct 21
Utility
ffxk0k3arkono1o4m8n4uz6xuody6tq75uueid774fs9tvh5eeezaf7
24 Mar 22
A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene.
Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
Filed: 23 Sep 21
Utility
Corrected0wcn7dab2i3dg6wslrvfcpcexqcoc06 25p
17 Mar 22
Provided include materials and methods for treating Hemophilia A in a subject ex vivo or in vivo.
Alan Richard Brooks
Filed: 17 Oct 18
Utility
ppxjyhf9o hdo0gi6dz5tq
17 Mar 22
The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell.
Ryo Takeuchi, Akiko Noma, Shuying He, Abraham Scaria
Filed: 29 Mar 21